Skip to main content

Table 3 Literature review of peripheral T cell lymphoma

From: Primary non-Hodgkin lymphoma of the tongue base: the clinicopathology of seven cases and evaluation of HPV and EBV status

Name

year

Numberof Cases

Age/sex

Primary site of tongue

Cytologic Features

IHC characters and gene rearrangment

Clinical feature

Stage

IPI

Treatment

Survival (months)

Uherova P,et al. [12]

2002

1

56/M

small to intermediate, with round nuclei and abundant pale to clear cytoplasm, like marginal zone B-Cell lymphoma

CD3+,CD43+,CD45+; TCR+

May SA, et al. [13]

2007

1

40/F

right ventrolate

atypical small- to medium-sized lymphoid infiltrate with involvement of the overlying squamous epithelium. Having irregular nuclear contours and scant cytoplasm

CD2,3,4,5+ CD43+; TCR+ Ki-67 25%

nodule

IA

Low

CVD and CM

32 months free of disease until research published

Lee JH, et al. [14]

2014

1

59/M

right side of the tongue base

CD3+, TIA+, granzyme B+ CD56-Ki-67 80%

fungating mass

IIA

low

CHOP plus RT and VMAT

Died 17 months later

Narla S, et al. [15]

2016

1

50/F

left half of anterior portion

small lymphoid cells with scanty cytoplasm, irregular hyperchromatic nucleusand inconspicuous nucleoli

CD3,4,8+;TCR+Ki67 30–40%

nodule

I

low

No adjunctive therapy

1 year later lost followed up

  1. F: female; M: male; TCR: T cell rearrangement; CVD: cyclophosphamide, vincristine, anddexamethasone; CM: cytarabine and methotrexate; −: not mentioned;
  2. CHOP: C-cyclophosphamide H-doxorubicin (hydroxydaunomycin) O-vincristine P- prednisolone; RT: radiation therapy; VMAT: volumetric modulated arc therapy